A Phase 1 interventional study of SM17 for injection and SM17 placebo for injection in Atopic Dermatitis, sponsored by SinoMab BioScience Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by SinoMab BioScience Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.
Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 150th largest by enrollment of the 190 interventional ones that give a count, is one of 39 that started in 2023, is one of 38 in phase 1, and was the 156th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Sites in China
Ages 18–75
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 2–11
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–75
QuantX Biosciences, Inc. · Sites in China
Ages 18 mo–65 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 53 · Phase 2 76 · Phase 3 63 · Phase 4 5
First in 2011; this study’s year is marked. 39 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 164 across the 190 interventional studies, 472 across the 16 observational. Of the 114 that completed or were terminated, 22 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
183 of 206 have an industry lead sponsor. The 10 most frequent:
SinoMab BioScience Ltd is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
SinoMab BioScience Ltd has 3 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
27 of the studies in Dermatitis, Atopic with a site in China that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06775860Phase 3Beijing InnoCare Pharma Tech Co., Ltd.ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | 2026-11-25 |
| NCT07540442Phase 3Shanghai Mabgeek Biotech.Co.LtdA Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-01-05 |
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
| NCT06880276Phase 3Qilu Pharmaceutical Co., Ltd.Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | 2027-03 |
| NCT07386743Phase 3Jiangsu Genscend Biopharmaceutical Co., LtdA Phase III Study of GS101 Injection to Dupixent® | 2027-04 |
Add all 27 to your calendar (.ics) → With an account.
Among the 206 studies in Dermatitis, Atopic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a phase 1, randomized, double-blind, placebo-controlled trial conducted in Chinese Healthy Volunteers and Patients with moderate-to-severe Atopic Dermatitis
It aims to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of single and multiple doses of SM17 injection in healthy subjects . It also aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect and immunogenicity as well as preliminary efficacy in AD patients.
This trial consists of 2 parts:
Part 1 (Ph1a) trial of the study is a dose-ascending study to evaluate the safety, tolerability, pharmacokinetic characteristics of SM17 in Chinese healthy volunteers. Safety and PK profiles of SM17 in Chinese population will be established firstly in this study following single and multiple doses of SM17 injection, and possible differences to those of SM17 in US populations will also be evaluated.
Part2 (ph1b) trial of the study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and preliminary efficacy of SM17 in treating patients with moderate-to-severe atopic dermatitis(AD) following multiple doses of SM17 injections at two doses level of SM17 or placebo. PK/PD profiles, immunogenicity profile of SM17 in AD patients will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy Volunteers:
Eligible patients must have a history of inadequate response or intolerance to treatment with topical AD medications.
Exclusion Criteria:
Healthy volunteers:
Any laboratory parameter meeting the following criteria:
AD patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single ascending dose cohort 1, participants(HVs) will receive 70mg of SM17 or placebo intravenously in this cohort with randomization ratio 6:2
Drug: SM17 for injection · Other: SM17 placebo for injection
single ascending dose cohort 2, participants(HVs) will receive 200mg of SM17 or placebo intravenously in this cohort with randomization ratio 6:2
Drug: SM17 for injection · Other: SM17 placebo for injection
single ascending dose cohort 3, participants(HVs) will receive 600mg of SM17 or placebo intravenously in this cohort with randomization ratio 6:2
Drug: SM17 for injection · Other: SM17 placebo for injection
multiple doses cohort, participants(HVs) will receive consecutive doses of 600mg of SM17 or placebo intravenously, once every 2 weeks in this cohort with randomization ratio 6:2
Drug: SM17 for injection · Other: SM17 placebo for injection
treatment group for participants (AD patients) to receive lower consecutive dose of SM17 (200mg)intravenously once every 2 weeks until end of treatment
Drug: SM17 for injection
treatment group for participants (AD patients) to receive higher consecutive dose of SM17 (200mg)intravenously once every 2 weeks until end of treatment
Drug: SM17 for injection
control group for participants (AD patients) to receive placebo doses intravenously once every 2 weeks until end of treatment
Other: SM17 placebo for injection
SM17 monoclonal antibody for intravenous infusion use
placebo to be compared with SM17, excipient solution of SM17 monoclonal antibody without protein
Incidence of treatment emergent AEs in each cohort(Ph1a)
Safety and tolerability of SM17 in Chinese healthy volunteers administrated with SM17 or placebo intravenously. Treatment emergent AE was any unfavorable or unintended medical occurrence in each subject, including any abnormal changes in vital signs or lab testing with clinical significance judged by investigators, that happened during the period of receiving or after receiving the investigational product.
Time frame: Day 0 to Day85 (SAD cohorts), Day 0 to Day 113 (MD cohort)
Incidence of Treatment emergent AEs (TEAEs) in each treatment group(ph1b)
Safety and tolerability of SM17 in Chinese AD patients administrated with SM17 or placebo intravenously. Treatment emergent AE was any unfavorable or unintended medical occurrence in each subject, including any abnormal changes in vital signs or lab testing with clinical significance judged by investigators, that happened during the period of receiving or after receiving the investigational product. changes in vital signs and lab testing
Time frame: Week 0 to Week 16
Area under the plasma concentration versus time curve (AUC) in Chinese healthy volunteers
Serum Pharmacokinetic (PK) parameter of SM17 in Chinese healthy subjects administrated with SM17 intravenously
Time frame: 12 weeks following SM17 dose (SAD) or last dose (MD)
Immunogenicity
ADA positive rate in Chinese healthy volunteers
Time frame: Baseline to 12 weeks following SM17/placebo dose (SAD) or last dose(MD)
Area under the plasma concentration versus time curve (AUC) in Chinese AD patients
Pharmacokinetic parameter obtained from Chinese patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: Week 0 (baseline) to Week 16
Efficacy for treating AD - EASI50%
Portion of participants reaching response as EASI50(A 50% decrease in Eczema Area and Severity Index, which ranges from 0\~72, and a deeper decrease means better outcome) in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: Week12, Week 16
Efficacy for treating AD-EASI75%
Portion of participants reaching response as EASI75(A 75%50% decrease in Eczema Area and Severity Index, which ranged from 0\~72, and a deeper decrease means better outcome) in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: Week12, Week 16
Efficacy for treating AD-EASI90%
Portion of participants reaching response as EASI90(a 90% decrease in Eczema Area and Severity Index, which ranges from 0\~72, and a deeper decrease means better outcome) in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: Week12, Week 16
Efficacy for treating AD-EASI score change
EASI(Eczema Area and Severity Index) score(ranges 0\~72,higher score means worse disease condition) change from baseline and percentage change from baseline in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: Week2,4,6,8,10,12,16
Efficacy for treating AD-IGA 0/1%
Portion of participants reaching response as IGA 0/1 in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously. Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) score ranges from 0 to 4, with lower scores indicating less severe AD. IGA 0/1 is defined as scores of 0 or 1, indicating a clear or almost clear AD presentation, and with at least 2-point reduction from baseline at time of assessment.
Time frame: Week12, Week16
Efficacy for treating AD- PP-NRS
Change from baseline and Percentage change from baseline in PP-NRS weekly average score. PP-NRS is peak pruritus numeric rating scale, ranges 0\~10, with higher score indicating a more severe itch condition. PP-NRS is assessed by patients to evaluate the peak pruritus condition for the past 24 hrs. A weekly average score is calculated as mean value of PP-NRS scores of 7 consecutive days prior to the point of assessments (need at least scores from 4/7 days available required to get a valid weekly average score).
Time frame: Baseline (Week0) to Week 16
Efficacy for treating AD-NRS-4%
Portion of participants reaching response as NRS-4 in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously. PP-NRS is peak pruritus numeric rating scale, ranges 0\~10, with higher score indicating a more severe itch condition. NRS-4 is defined as at least 4 points reduction from baseline in weekly average score of PP-NRS. A weekly average score baseline is calculated as mean value of PP-NRS scores of 7 consecutive days prior to treatments (need at least scores from 4/7 days available to get a valid weekly average score baseline).
Time frame: Week2,4,6,8,10,12,16
Efficacy for treating AD-BSA%
Change from baseline in Body Surface Area%(BSA%) with AD involvement, with a larger BSA% indicating a more severe disease condition.
Time frame: Week 2,4,6,8,10,12,16
Efficacy in treating AD-SCORAD
Change from baseline and percentage change from baseline in SCORAD (SCORing Atopic Dermatitis), ranges 0\~103, with higher score indication a worse disease condition.
Time frame: Week 4,8,10,12,16
Efficacy for treating AD-POEM
Change from baseline and Percentage change from baseline in POEM (Patient-Oriented Eczema Measure scores, range 0-28), with higher score indicating a worse disease condition.
Time frame: Week2,4,6,8,10,12,16
Efficacy for treating AD-DLQI
Change from baseline in DLQI score (Dermatology Life Quality Index, range 0\~30, with higher score indicating a higher disease burden).
Time frame: Week2,4,6,8,10,12,16
Immunogenicity
ADA positive rate in Chinese patients with moderate-to-severe AD treated by SM17/placebo intravenously
Time frame: Week 0~16
PD biomarkers- total IgE
Serum total IgE concentration (mg/L) tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo
Time frame: Week0, 4, 8, 10, 12, 16
Peak Plasma Concentration (Cmax) in healthy volunteers and AD patients
PK parameter(Cmax) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b
Time to peak (Tmax)
PK parameter(Tmax) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b
Elimination half-life (T1/2)
PK parameter(T 1/2) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b
Elimination Rate Constant (Kel)
PK parameter(Kel) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b
Total drug clearance from plasma (CL)
PK parameter(CL) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b
Apparent volume of distribution at steady state after extravascular administration (Vz)
PK parameter(Vz) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously
Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b
PD biomarker- Eosinophil counts
Serum Eosinophil counts tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo
Time frame: Week0,2,4,6, 8, 10, 12, 16
PD biomarker- Tarc
Serum Tarc (CCL17) concentration (pg/mL) tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo
Time frame: Week0, 4, 8, 10, 12, 16
PD biomarker-Eotaxin-3
Serum Eotaxin-3 (CCL-26) concentration (pg/mL) tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo
Time frame: Week0, 4, 8, 10, 12, 16
PD biomarker- Periostin
Serum Periostin concentration (ng/mL) tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo
Time frame: Week0, 4, 8, 10, 12, 16
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in Mar 2025, 16 months.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 16 months is above that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SinoMab BioScience Ltd